News: Northwest Biotherapeutics Inc (NWBO.OQ)

NWBO.OQ on NASDAQ Stock Exchange Capital Market

6.26USD
12:51pm EDT
Price Change (% chg)

$-0.18 (-2.80%)
Prev Close
$6.44
Open
$6.44
Day's High
$6.45
Day's Low
$6.25
Volume
30,382
Avg. Vol
261,059
52-wk High
$10.60
52-wk Low
$3.10

Search Stocks
Select another date:

Thu, Jun 19 2014

UPDATE 1-Northwest Bio drug for inoperable tumors safe so far -researcher

June 19 - An experimental Northwest Biotherapeutics Inc drug for inoperable tumors has shown no signs of toxicity in an ongoing safety trial being conducted at M.D. Anderson Cancer Center, the trial's researcher said on Thursday.

CORRECTED-Northwest Bio drug for inoperable tumors safe so far -researcher

June 19 - An experimental Northwest Biotherapeutics Inc drug for inoperable tumors has shown no signs of toxicity in an ongoing safety trial being conducted at M.D. Anderson Cancer Center, the trial's researcher said on Thursday.

Exclusive: Germany OKs Northwest Bio brain cancer drug, shares soar

- Germany has granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug in the country, the company said, and its stock jumped as much as 36 percent.

Panel recommends Northwest Bio brain-cancer trial continue

- Northwest Biotherapeutics Inc on Friday said an independent monitoring board had recommended that a late-stage study of its experimental brain-cancer treatment be continued, based on an interim safety review.

Panel recommends Northwest Bio brain-cancer trial continue

March 7 - Northwest Biotherapeutics Inc on Friday said an independent monitoring board had recommended that a late-stage study of its experimental brain-cancer treatment be continued, based on an interim safety review.

Tiny Northwest Biotherapeutics aims to dominate brain cancer

NEW YORK - Ten years ago, cash-strapped biotechnology company Northwest Biotherapeutics Inc was down to three employees and one week from closing its doors when a financial backer came forward at the annual JP Morgan Healthcare Conference.

RPT-FEATURE-Tiny Northwest Biotherapeutics aims to dominate brain cancer

NEW YORK, Feb 26 - Ten years ago, cash-strapped biotechnology company Northwest Biotherapeutics Inc was down to three employees and one week from closing its doors when a financial backer came forward at the annual JP Morgan Healthcare Conference.

FEATURE-Tiny Northwest Biotherapeutics aims to dominate brain cancer

NEW YORK, Feb 26 - Ten years ago, cash-strapped biotechnology company Northwest Biotherapeutics Inc was down to three employees and one week from closing its doors when a financial backer came forward at the annual JP Morgan Healthcare Conference.

Select another date:
Search Stocks